全球流感诊断与治疗市场：未来预测（2025-2030）

流感诊断和治疗市场预计将从 2025 年的 427.19 亿美元成长到 2030 年的 613.42 亿美元，复合年增长率为 7.50%。

预计未来五年，流感诊断和治疗市场将迎来显着成长，这得益于全球流感高发，尤其是在医疗保健资源匮乏的地区。主要市场参与企业加大研发投入，以提高产品品质并拓展产品组合，预计将在预测期（2024-2029年）进一步推动市场成长。市场对改善健康状况（尤其是高风险族群健康）的日益关注，支撑了市场的扩张。

主要成长要素

全球不断攀升的流感疫情仍是市场成长的主要驱动力。在北美，甲型流感病毒占据主导地位，约占成人流感住院病例的80%。欧洲和亚太等地区流感发生率的上升也显着推高了市场需求。流感具有传染性，其特征是发烧、喉咙痛、干咳和肌肉酸痛等症状，可能导致老年人、孕妇、婴儿和免疫力缺乏低下者等弱势群体患上重病甚至死亡，这加剧了对有效诊断和治疗方案的需求。

全球人口老化，尤其是在日本、义大利和德国等国家，进一步推动了市场成长。免疫力较弱的长者需要加强流感诊断和治疗，这增加了对专业套件和服务的需求。这些地区拥有完善的医疗保健体系，这推动了先进诊断和治疗解决方案的采用。

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业景气

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

5. 全球流感诊断与治疗市场（以流感类型）

• 介绍
• A型
• B型
• 其他的

6. 全球流感诊断与治疗市场（依产品提供）

• 介绍
• 诊断
  • 快速流感诊断检测
  • 快速分子检测
  • RT-PCR和NAAT
  • 萤光试验
  • 家用流感检测套组
• 治疗
  • 抗病毒药物
  • 疫苗
  • 其他的

7. 全球流感诊断与治疗市场（依年龄层）

• 介绍
• 0-14岁
• 15-64岁
• 65岁或以上

8. 全球流感诊断与治疗市场（依给药方式）

• 介绍
• 口服
• 鼻内
• 注射

9. 全球流感诊断与治疗市场（依最终使用者）

• 介绍
• 医院和医院检查室
• 门诊
• 药局和零售诊所
• 参考实验室
• 居家医疗/自我检测用户

第十章 全球流感诊断与治疗市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第十章竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 企业合併（M&A）、协议与合作
• 竞争仪錶板

第十一章 公司简介

• QuidelOrtho Corporation
• F. Hoffmann-La Roche AG
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• SA Scientific, Ltd.
• Sekisui Diagnostics, LLC
• Meridian Bioscience, Inc.
• Oxford Biosystems Ltd.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline plc
• Abbott Laboratories
• Danaher Corporation
• Sanofi SA
• Hologic, Inc.
• Luminex Corporation
• DiaSorin SpA

第十二章 附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要利益
• 分析方法
• 简称

The Global Flu Diagnostic And Treatment Market is expected to grow from USD 42.719 billion in 2025 to USD 61.342 billion in 2030, at a CAGR of 7.50%.

The global flu diagnostic and treatment market is expected to experience significant growth over the next five years, driven by the high prevalence of influenza worldwide, particularly in regions with limited healthcare access. Rising investments in research and development by key market players to enhance product quality and expand offerings are anticipated to further propel market growth during the forecast period (2024-2029). The focus on improving health outcomes, especially for high-risk populations, underscores the market's expansion.

Key Growth Drivers

The increasing prevalence of influenza globally remains a primary driver of market growth. In North America, influenza A viruses dominate, accounting for approximately 80% of adult influenza-related hospitalizations. The growing incidence of flu in regions such as Europe and Asia Pacific also contributes significantly to market demand. The need for effective diagnostic and treatment solutions is amplified by the disease's contagious nature, characterized by symptoms like fever, sore throat, dry cough, and muscle pain, which can lead to severe illness or death in vulnerable groups, including the elderly, pregnant women, infants, and immunocompromised individuals.

The aging global population, particularly in countries like Japan, Italy, and Germany, further fuels market growth. Older adults, with weaker immune systems, require enhanced flu diagnostics and treatments, increasing demand for specialized kits and services. Well-established healthcare systems in these regions support the adoption of advanced diagnostic and treatment solutions.

Market Segmentation

By Flu Type

• The market is segmented into Type A and Type B influenza viruses. Type A dominates due to its higher prevalence and greater number of clinically diagnosed cases and hospitalizations compared to Type B. The Type A segment is expected to maintain a significant market share through 2029. While Type B flu has a lower incidence, its growing prevalence, particularly in the Asia Pacific region, is anticipated to drive modest growth in this segment over the forecast period.

By End-User

• The market is categorized into hospital laboratories, outpatient clinics, and reference laboratories. Outpatient clinics are projected to exhibit notable growth due to their cost-effective, point-of-care treatment offerings. Hospital laboratories, however, are expected to retain a significant market share, driven by their ability to provide long-term care and perceived reliability. Reference laboratories also contribute to the market but to a lesser extent.
• Geographical Outlook
• The Asia Pacific region is poised for robust growth, fueled by the rising prevalence of influenza in countries like India, China, and Indonesia, coupled with increasing healthcare expenditure in developing nations. North America is expected to maintain a substantial market share, supported by well-established healthcare systems in the U.S. and Canada and high healthcare spending. These factors collectively position North America and Asia Pacific as key regions driving the global flu diagnostic and treatment market through 2029.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
• What do businesses use our reports for?
• Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Global Flu Diagnostic and Treatment Market Segmentation:

By Type of Flu

• Type A
• Type B
• Others

By Offering

• Diagnostics
• Rapid Influenza Diagnostic Test
• Rapid Molecular Assay
• RT-PCR & NAATs
• Immunofluorescence Assays
• At-Home Flu Testing Kits
• Therapeutics
• Antiviral Medications
• Vaccines
• Others

By Age Group

• 0-14 Years
• 15-64 Years
• >=65 Years

By Mode of Administration

• Oral
• Intranasal
• Injectable

By End-User

• Hospitals & Hospital Laboratories
• Outpatient Clinic
• Pharmacies & Retail Clinics
• Reference Laboratories
• Home Care/Self-Test Users

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• UAE
• Other
• Asia Pacific
• China
• Japan
• South Korea
• India
• Thailand
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU

• 5.1. Introduction
• 5.2. Type A
• 5.3. Type B
• 5.4. Others

6. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Rapid Influenza Diagnostic Test
  • 6.2.2. Rapid Molecular Assay
  • 6.2.3. RT-PCR & NAATs
  • 6.2.4. Immunofluorescence Assays
  • 6.2.5. At-Home Flu Testing Kits
• 6.3. Therapeutics
  • 6.3.1. Antiviral Medications
  • 6.3.2. Vaccines
  • 6.3.3. Others

7. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP

• 7.1. Introduction
• 7.2. 0-14 Years
• 7.3. 15-64 Years
• 7.4. >=65 Years

8. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY MODE OF ADMINISTRATION

• 8.1. Introduction
• 8.2. Oral
• 8.3. Intranasal
• 8.4. Injectable

9. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER

• 9.1. Introduction
• 9.2. Hospitals & Hospital Laboratories
• 9.3. Outpatient Clinic
• 9.4. Pharmacies & Retail Clinics
• 9.5. Reference Laboratories
• 9.6. Home Care/Self-Test Users

10. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. USA
  • 10.2.2. Canada
  • 10.2.3. Mexico
• 10.3. South America
  • 10.3.1. Brazil
  • 10.3.2. Argentina
  • 10.3.3. Others
• 10.4. Europe
  • 10.4.1. Germany
  • 10.4.2. France
  • 10.4.3. United Kingdom
  • 10.4.4. Spain
  • 10.4.5. Others
• 10.5. Middle East and Africa
  • 10.5.1. Saudi Arabia
  • 10.5.2. UAE
  • 10.5.3. Others
• 10.6. Asia Pacific
  • 10.6.1. China
  • 10.6.2. India
  • 10.6.3. Japan
  • 10.6.4. South Korea
  • 10.6.5. Indonesia
  • 10.6.6. Thailand
  • 10.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. QuidelOrtho Corporation
• 11.2. F. Hoffmann-La Roche AG
• 11.3. Becton, Dickinson and Company
• 11.4. Thermo Fisher Scientific Inc.
• 11.5. SA Scientific, Ltd.
• 11.6. Sekisui Diagnostics, LLC
• 11.7. Meridian Bioscience, Inc.
• 11.8. Oxford Biosystems Ltd.
• 11.9. Pfizer Inc.
• 11.10. Bayer AG
• 11.11. GlaxoSmithKline plc
• 11.12. Abbott Laboratories
• 11.13. Danaher Corporation
• 11.14. Sanofi S.A.
• 11.15. Hologic, Inc.
• 11.16. Luminex Corporation
• 11.17. DiaSorin S.p.A.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations